NOT-AR-21-019: Notice of NIAMS Participation in NOT-EB-21-001 "Notice of Special Interest (NOSI): Small Business Initiatives for Innovative Diagnostic Technology for Improving Outcomes for Maternal Health"

Notice of NIAMS Participation in NOT-EB-21-001 "Notice of Special Interest (NOSI): Small Business Initiatives for Innovative Diagnostic Technology for Improving Outcomes for Maternal Health"

Notice Number:

NOT-AR-21-019

Key Dates

Release Date:

March 11, 2021

Related Announcements

NOT-EB-21-001 - Notice of Special Interest (NOSI): Small Business Initiatives for Innovative Diagnostic Technology for Improving Outcomes for Maternal Health

Issued by

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Purpose

The purpose of this Notice is to indicate that National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) is participating in NOT-EB-21-001 "Notice of Special Interest (NOSI): Small Business Initiatives for Innovative Diagnostic Technology for Improving Outcomes for Maternal Health."

NIAMS supports research into the causes, treatment, and prevention of arthritis and musculoskeletal and skin diseases(https://www.niams.nih.gov/about). NIAMS is interested in small business technological innovations that address maternal morbidity and mortality within the scope of the NIAMS mission. For this NOSI, potential NIAMS areas of interest related to maternal mortality and morbidity include, but not limited to: systemic rheumatic and autoimmune diseases such as rheumatic arthritis, lupus, and systemic scleroderma; musculoskeletal diseases and conditions such as muscular dystrophy, osteogenesis imperfecta, and bone deformities.

NOTE: It is not the intent of NIAMS to support clinical trials through the SBIR/STTR mechanism. Applicants who wish to submit clinical trial applications to the NIAMS are encouraged to utilize one of the NIAMS funding opportunities listed at https://www.niams.nih.gov/grants-funding/conducting-clinical-research/investigator-clinical-trial-policies.

NIAMS will accept responsive applications submitted to the following FOAs:

Activity Code	FOA	First Available Due Date
R41, R42	PA-20-265- PHS-2020-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)	September 5, 2021
R43, R44	PA-20-260– PHS 2020-2 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)	September 5, 2021
R41, R42, R43, R44	PA-20-272– Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)	Due dates may vary by awarding IC. See the awarding IC's web site. Applicants may also contact their respective awarding IC.

Inquiries

Please direct all inquiries to:

Xibin Wang
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Phone: 301-451-3884
Email: [email protected]